Tag Archives: NervGen Pharma Corp

NervGen looking to use their technology to revolutionize nerve damage treatment

NervGen Pharma (CVE:NGEN) President and CEO Ernest Wong sat down with Steve Darling from Proactive Investors Vancouver to talk about the pharma company that has technology that hopes to regenerate nerve damage, that damage can be spinal cord or peripheral. … Continue reading

Posted in Regenerative Medicine, spinal cord injury research, Uncategorized | Tagged , ,

NERVGEN PHARMA COMPLETES $10 MILLION INITIAL PUBLIC OFFERING

Vancouver, Canada. March 13, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering (“IPO”) of … Continue reading

Posted in Ligand, Regenerative Medicine, spinal cord injury research | Tagged , ,

Dr Jerry Silver – Spinal Cord Damage and Emerging Treatments

“Injuries to the spinal cord can cause permanent paralysis and even lead to death, with little to no hope of regaining lost functions once the trauma has occurred. Dr Jerry Silver and his team at Case Western Reserve University Medical … Continue reading

Posted in Chronic Spinal Cord Injury Research, Ligand, Regenerative Medicine, spinal cord injury research | Tagged , ,

Worldwide licensing agreement made on peptide developed in Silver laboratory at Case Western Reserve University

Read the Full Article at Globe Newswire.   VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen”), in Vancouver, and Case Western Reserve University (“Case Western Reserve”) in Cleveland have entered into an exclusive worldwide licensing agreement to research, develop and … Continue reading

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research | Tagged , , ,